Antibody Therapeutics Inc. has disclosed integrin receptor antagonists reported to be useful for the treatment of pulmonary fibrosis, renal fibrosis and hepatic fibrosis.
Atherosclerosis represents a chronic inflammatory disease characterized by the accumulation of lipid-laden macrophage foam cells within arterial walls, serving as the underlying pathological basis for ...